Ribostat™ Research Presented at ARVO 2019

The results of research showing the advantages of Ribostat for corneal cross-linking were presented today at the Association for Research in Vision & Ophthalmology Annual Meeting. Dr. Glen Gum of Absorption Systems, a leading preclinical research laboratory, revealed results of an animal study entitled “The Effect of NaI on Stromal Loading, Distribution and Degradation of CXLO Corneal Strengthening Solution after Topical Application and UVA Exposure in New Zealand White Rabbits.” The levels of riboflavin photosensitizer were monitored throughout crosslinking with ultraviolet (UVA) light, separately using Ribostat and an otherwise equivalent formulation without iodide. The Ribostat formulation showed significantly higher penetration across the epithelium. Once there, Ribostat photo-protected the riboflavin, resulting in significantly less degradation of riboflavin throughout treatment. The research supports the conclusion that the patented addition of iodide in Ribostat results in greater crosslinking efficiency without removal of the epithelium and without repeated application throughout the treatment.